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Over the past two decades, the International Association for
the Study of Lung Cancer (IASLC) Staging Project has been a
steady source of evidence-based recommendations for the
TNM classification for lung cancer published by the Union
for International Cancer Control and the American Joint
Committee on Cancer. The Staging and Prognostic Factors
Committeeof the IASLC is nowissuinga call forparticipation in
the next phase of the project, which is designed to inform the
ninth edition of the TNM classification for lung cancer.
Following the case recruitment model for the eighth edition
database, volunteer site participants are asked to submit data
on patients whose lung cancer was diagnosed between
January 1, 2011, and December 31, 2019, to the project by
means of a secure, electronic data capture system provided by
Cancer Research And Biostatistics in Seattle, Washington.
Alternatively, participantsmay transfer existing data sets. The
continued success of the IASLC Staging Project in achieving its
objectives will depend on the extent of international partici-
pation, the degree to which cases are entered directly into the
electronic data capture system, and how closely externally
submitted cases conform to the data elements for the project.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The International Association for the Study of Lung
Cancer (IASLC) established an international staging
committee, now referred to as the Staging and Prog-
nostic Factors Committee (SPFC), in 1997 to collect and
combine lung cancer data sets to inform changes to the
TNM staging system for lung cancer with representation
worldwide and including all treatment modalities. The
TNM staging system was developed by Pierre Denoix
between 19431 and 1952,2 and until the IASLC initiative,Journal of Thoracic Oncology Vol. 13 No. 6: 801-809
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based almost exclusively on a single data set established
by Dr. Clifton Mountain at M. D. Anderson Cancer
Center3 in the United States.
This first phase of the staging project resulted in
a database of 81,495 evaluable lung cancer cases
from 45 sources in 20 countries that were diagnosed
from 1990 to 2000 and included all treatment
modalities.4 This database was the foundation for the
committee’s core recommendations for changes to the
staging system, which was published in 20075–9 along
with additional publications on SCLC,10,11 carcinoid tu-
mors,12 and prognostic factors for lung cancer in gen-
eral13 and surgically managed NSCLC.14 In planning for
future collaboration, a new international nodal map15
was proposed to resolve differences in the two maps
in use at the time, and standard criteria were proposed
to measure depth of pleural invasion.16 All of these
recommendations were adopted by the Union for Inter-
national Cancer Control (UICC) and the American Joint
Committee on Cancer (AJCC) in 2009 in the seventh
editions of their staging manuals for lung cancer.17,18
They were also published in the first edition of the
IASLC Staging Manual in Thoracic Oncology and the
IASLC Staging Handbook in Thoracic Oncology.19,20 A
catalog of presentation slides describing the recom-
mendations and the supportive data is also posted on the
IASLC website for public use.
The second phase of the staging project began in
2009 with a call to participants to contribute data using
a centralized, electronic data capture (EDC) system.21
Alternatively, participants were encouraged to collect
the published data elements using their own platforms
and still contribute standardized data sets in this way.
These data elements were drafted in a series of
meetings of the chair and subcommittee chairs in
2007–2008 and circulated among the full committee
membership for review. Ultimately, a number of large
national registries were combined with the EDC data to
yield a database of 94,708 patients around the world
with lung cancer diagnosed from 1999 to 2010.
Approximately 6% of the cases in this second interna-
tional database were submitted according to the pre-
scribed data dictionary, including 4667 cases entered
through the EDC and a database of 1427 from Memo-
rial Sloan Kettering Cancer Center.22 From this second,
international database, the IASLC SPFC developed
recommendations toward the eighth edition of the TNM
staging system. These recommendations were pub-
lished in 2015, 2016, and 201723–33 and were once
again accepted by the UICC34 and AJCC35 in 2017 (with
AJCC implementation effective in 2018) and included in
the second edition of the IASLC Staging Manual inThoracic Oncology and the IASLC Staging Handbook in
Thoracic Oncology.36,37
Data Elements for the Project
The project is now entering its third cycle, with the
goal of developing recommendations for the ninth edi-
tion of TNM. The population to be studied consists of
patients with lung cancer newly diagnosed between
January 1, 2011, and December 31, 2019. The data
elements and other documentation describing the
project, including application materials, a protocol to
facilitate ethics review, and screenshots of the data entry
screens, are posted online at https://iaslc.crab.org/LC/
LCStagingProject9Ed.pdf. Briefly, data elements include
patient characteristics; baseline laboratory values and
results of pulmonary function tests and positron emis-
sion tomography; an indication of which clinical tests
were used to establish pretreatment T, N, and M cate-
gories; clinical TNM category plus supporting evidence
and pathologic TNM category; treatment; molecular
markers; and survival.
Pretreatment TNM category is collected for all cases;
postsurgical or pathologic TNM category is collected
if resection of the primary tumor is attempted. T
descriptors include size and degree of tumor extension,
with further description of pretreatment carcinomatous
lymphangitis and attributes of the primary tumor
documented during the surgical procedure that are not
currently T descriptors. Nodal station involvement is
described by station by using the IASLC 2009 nodal map,
with additional collection of the number of nodes
sampled, the number of positive nodes, and the presence
of extracapsular involvement. M descriptors qualify the
presence of pleural/pericardial effusions, contralateral/
bilateral lung nodules, and contralateral/bilateral
pleural nodules and quantify metastatic lesions at spe-
cific distant sites. Genetic biomarkers, copy number
alterations, and protein alterations identified at any
time during the course of systemic treatment, as well as
the specific systemic agents administered, are new data
elements in the ninth edition effort, introduced by the
recently created Molecular Taskforce Subcommittee of
the SPFC.
In all, the database consists of 474 fields collected in
18 data forms. Although the majority of these fields are
check boxes, entering a complete baseline form set can
be expected to take 1 to 2 hours. This time estimate is
based on the October 2017 release of the EDC system
(before molecular forms were added) and reflects the
experience of the first institutions in using the new
system—primarily, the Cooperative Group of Broncho-
genic Carcinoma III–Spanish Society of Pulmonology and
Thoracic Surgery.
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of the TNM Classification
The initial retrospective staging project was based
exclusively on existing data sets that were not designed
to address questions about lung cancer staging, and the
limitations of this method of case selection have been
described. For example, proposals for change regarding
T descriptors were limited to tumor size, additional
tumor nodules, and pleural effusion in the seventh
edition recommendations partly because of a lack of
detail in the data submitted to explore other questions
regarding tumor extension.22 In the eighth edition
database, many of the large staging-related data sets and
registry data were pivotal in providing the empirical
evidence on which the T1a, T1b, and T1c categories are
based and provided context to the stage groupings
analysis. However, with the exception of the Japanese
series, these data sets were less informative to decisions
regarding atelectasis (reclassified as T2 whether partial
or total) or involvement of the main bronchus (reclas-
sified as T2) or diaphragm (reclassified as T4), for
example.22 They also generally lacked the distinction
between single and multiple distant metastatic lesions
necessary to explore the committee’s predefined objec-
tives regarding M descriptors. By contrast, the subset of
cases that were directly entered through the EDC from
Spain, China, and other countries in Europe and South
America were fundamental to the eighth edition rec-
ommendations to subdivide extrathoracic metastases
into M1b (single lesion) and M1c (multiple lesions), as
these data suggested that the M1b category had a
prognosis similar to that of the M1a category and
significantly different from that of the M1c category.25
For these reasons, increasing online registration
through the EDC is the highest priority of the IASLC SPFC
in terms of recruitment of cases in the ninth edition
database.
The primary aim of the IASLC Lung Cancer Staging
Project is to inform future revisions to the staging
criteria. The research objectives related to the T, N, and
M descriptors, as well as other nonanatomic consider-
ations for staging and prognosis, are as outlined in
Table 1. Further implementation and evaluation of
prognostic differences based on tumor size will be a
special area of focus for the ninth edition, given the
increasing emphasis on tumor size as a determinant of T
classification and the new guidelines regarding the
measurement and pathologic staging of adenocarcinoma
in situ, minimally invasive adenocarcinoma, and lepidic
predominant adenocarcinoma,38 which were added to
the WHO Classification in 2015.39 Other burning ques-
tions for the ninth edition in particular include the
assessment of the prognostic impact of single versusmultiple station involvement in N1 and N2 locations,
skip N2 disease, and reassessment of newly imple-
mented proposals regarding multiple lesions after
increasing the follow-up for survival of these patients.
Although criteria for complete resection in lung cancer
were already published in 2005 by an IASLC working
group specifically looking at residual (R) disease, the
precise impact of the different R categories on survival
has not been clearly established.40 A recent publication41
and data presented at the presidential session of the
18th World Conference on Lung Cancer42 show that
patients with uncertain resections have a poorer
outcome that do patients with complete (R0) resections.
Most patients in the uncertain category have inadequate
lymph node dissection; so, particular attention should be
paid to mediastinal staging and intraoperative lymph
node evaluation. Guidelines for surgical evaluation
during staging and definite treatment of lung cancer will
be provided, with clarification of the description of the
different lymph node stations for specific surgical pur-
poses. Also, oligometastatic disease is currently a major
topic of interest, with controversial opinions regarding
the best management. More prospective data will pro-
vide useful information regarding refinement of the
category M1b: is there a significant survival difference
between patients with one, two, or three metastases in
one specific distant organ? Are these survival rates
comparable to the survival rates in patients with two or
three distant metastases in two or three different or-
gans? Finally, survival models should be developed that
incorporate additional biomarker profiles and specific
gene mutations as prognostic variables in addition to
anatomic TNM and classic predictors of survival such as
age, sex, and performance status. In this respect, the
creation of prognostic groups combining anatomic and
nonanatomic parameters will be one of the most chal-
lenging activities of the third phase of the IASLC Staging
Project.
Call to Participation
At this time, the IASLC SPFC is issuing a call to
participation to all who wish to contribute data to this
effort to ensure that decisions regarding the staging of
lung cancer are based on sound empirical evidence. The
current time line for the project, as shown in Table 2,
allows recruitment of cases through 2019, with follow-
up for survival through 2021, for the ninth edition rec-
ommendations to be developed in 2022. As in past years,
these findings will be shared with the worldwide lung
cancer community through a series of publications to be
submitted to the Journal of Thoracic Oncology. The rec-
ommendations and supportive data will also be sub-
mitted to the UICC and AJCC for consideration in the next
Table 1. Study Objectives
Component Objective
T a) Assess the prognostic impact of tumor size
b) Assess the classification capacity of each descriptor defining T status
c) Study new conditions not included in the present T (e.g., differences between parietal pleura invasion and rib invasion)
N a) Assess the prognostic impact of N status
b) Assess the prognostic impact of
i. Nodal extent (single vs. multiple station involvement in N1 and N2 locations)
ii. Number of involved lymph nodes
iii. Lymph node ratio (i.e., number of involved lymph nodes divided by the number of removed lymph nodes)
iv. Nodal size (i.e., largest involved node within the relevant N category)
v. Individual nodes involved in each nodal category
c) Assess the prognostic impact of extracapsular extension
d) Assess the prognostic impact of the N3 nodal location (i.e., contralateral mediastinum and ipsilateral or contralateral
supraclavicular fossa)
M a) Assess the prognostic impact of M status
b) Assess the prognostic impact of
i. Single metastasis in a single organ
ii. Multiple metastases in a single organ
iii. Multiple metastases in several organs
Other a) Assess the prognostic impact of histologic type and grade
b) Assess the reliability of staging methods utilized in clinical staging (for those tumors with pretreatment and postsurgical
classification)
c) Assess the prognostic impact of complete, incomplete, and uncertain resections according to the proposed definitions of
the International Association for the Study of Lung Cancer
d) Assess the prognostic impact of clinical factors, including comorbidity and pulmonary function tests
e) Assess the prognostic impact of maximum standard uptake value (SUVmax) at the primary site and in any positive nodal
sites for those patients with positron emission tomography scans in the pretreatment staging
Prognostic
groups
a) Assess the prognostic relevance of individual molecular parameters
b) Create prognostic groups based on the combination of anatomic and nonanatomic parameters, including molecular
markers, clinical and epidemiological features, and other parameters, such as lung function tests, blood analyses and
SUVmax
SUVmax, maximum standardized uptake value.
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be published in 2024.
Contributing to the IASLC database is both personally
and professional rewarding for those interested in
improving lung cancer staging on account of the long-
standing nature of this international project, which has
proved to be very successful in the past two revisions
of the TNM classifications of thoracic maliganancies.
Contributors are acknowledged in the appendix of every
paper published by the committee. In addition, contri-
bution of cases through the EDC system provides sites
with the ability to download institutional data, withTable 2. Time Line
Year: 2018 2019 2020 2021
Activity: EDC case registration
(retrospective to 2011)
Follow-up and
preliminary analysis
EDC, electronic data capture; UICC, Union for International Cancer Control; AJrange checks and data consistency checks having been
applied.
Each institution that contributes data to the project
will retain full access and publishing rights to its own
data; however, the collective database is the property of
the IASLC, and Cancer Research And Biostatistics is
responsible for its management, storage, and analysis.
Publications related to the objectives of the IASLC SPFC
(i.e., publications providing recommendations for
changes in the TNM classification for lung cancer) will be
planned, researched, analyzed, and written by the
members of the respective subcommittees and will2022 2023 2024
Final data
analysis
Publication of
recommendations in
the Journal of
Thoracic Oncology
Publication of the
ninth edition of the
TNM classification by
the UICC and AJCC
Submission of
recommendations to
the UICC and AJCC
CC, American Joint Committee on Cancer.
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cations regarding the seventh and eighth edition pro-
posals: chair of the subcommittee, members of the
subcommittee in alphabetical order, chair of the IASLC
SPFC on behalf of the committee, and participating
institutions.
Readers with ideas on the inclusion of elements not
included in the present data set should contact the chair
of the IASLC SPFC, Hisao Asamura, MD (thymoma1983@
gmail.com), and explain the rationale behind these
proposals.
There are several ways to become a member of the
IASLC SPFC: (1) by invitation (invitations are sent to
specialists who have shown special interest in staging or
who can contribute cases from their institutions or sci-
entific societies, (2) by recommendation from an IASLC
board member (these are usually included in point 1),
(3) by application (the IASLC has a system of self-
nomination to apply for membership on the IASLC
different committees; the applications are reviewed by
the IASLC and discussed with the chair of the SPFC and
chairs of the respective subcommittees), and (4) by
contacting the chair of the SPFC and expressing interest
in participating.
In all cases, membership in the SPFC is subject to
approval by the president and board of directors of the
IASLC. Current active IASLC membership is generally
required to serve on IASLC committees, though excep-
tional circumstances may be considered at the discretion
of the SPFC chair.
To indicate your interest in contributing data to the
project or to obtain more information, please send an
email to webhelpIASLC@crab.org (Supplementary Fig. 1)
with IASLC Lung Cancer Staging Project in the subject
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